Inhibition of the MEK-ERK signaling pathway reverses acquired osimertinib resistance in NSCLC attributed to AXL overexpression.
Targeting a specific signaling pathway reverses drug resistance in lung cancer, offering a potential solution for treatment-resistant tumors.
This diagnostic validation study examined Inhibition of the MEK-ERK signaling pathway reverses acquired osimertinib resistance in NSCLC attributed to AXL overexpression. The abstract reports that Our findings provide preclinical mechanistic support for potential use to targeting MEK-ERK signaling in AXL-associated osimertinib resistance and forfurther validation in patient-derived and clinical models.
What the study was
- Study design
- Diagnostic validation study
- Population
- Human participants
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Life Sci
Why it surfaced
Diagnostic validation study; directly matches Precision oncology and genomic medicine. Conservative abstract-level score 8/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.